437 related articles for article (PubMed ID: 25962155)
1. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
[TBL] [Abstract][Full Text] [Related]
2. Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
Brackmann M; Stasenko M; Uppal S; Erba J; Reynolds RK; McLean K
BMC Cancer; 2018 Feb; 18(1):172. PubMed ID: 29426293
[TBL] [Abstract][Full Text] [Related]
3. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
4. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
5. Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
Torres D; Hou X; Bale L; Heinzen EP; Maurer MJ; Zanfagnin V; Oberg AL; Conover C; Weroha SJ
PLoS One; 2019; 14(11):e0224564. PubMed ID: 31751381
[TBL] [Abstract][Full Text] [Related]
6. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
[TBL] [Abstract][Full Text] [Related]
7. Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy.
Harris FR; Zhang P; Yang L; Hou X; Leventakos K; Weroha SJ; Vasmatzis G; Kovtun IV
Mol Oncol; 2019 Feb; 13(2):132-152. PubMed ID: 30499260
[TBL] [Abstract][Full Text] [Related]
8. A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts.
Becker MA; Haluska P; Bale LK; Oxvig C; Conover CA
Mol Cancer Ther; 2015 Apr; 14(4):973-81. PubMed ID: 25695953
[TBL] [Abstract][Full Text] [Related]
9. Carcinosarcoma of the ovary.
Silasi DA; Illuzzi JL; Kelly MG; Rutherford TJ; Mor G; Azodi M; Schwartz PE
Int J Gynecol Cancer; 2008; 18(1):22-9. PubMed ID: 17451459
[TBL] [Abstract][Full Text] [Related]
10. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
11. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
Ricci F; Guffanti F; Damia G; Broggini M
Mol Cancer; 2017 May; 16(1):97. PubMed ID: 28558767
[TBL] [Abstract][Full Text] [Related]
12. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.
Beltran PJ; Calzone FJ; Mitchell P; Chung YA; Cajulis E; Moody G; Belmontes B; Li CM; Vonderfecht S; Velculescu VE; Yang G; Qi J; Slamon DJ; Konecny GE
Clin Cancer Res; 2014 Jun; 20(11):2947-58. PubMed ID: 24727326
[TBL] [Abstract][Full Text] [Related]
13. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
14. [Carcinosarcoma of the ovary treated with paclitaxel and carboplatin chemotherapy - a report of 4 cases].
Otsuka I; Takaya H; Takagi K; Tanaka A; Kaseki H; Izuta C; Sato M; Matsuura T; Suzuki Y
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1249-53. PubMed ID: 24047791
[TBL] [Abstract][Full Text] [Related]
15. Carcinosarcoma of the ovary-a case series.
Rutledge TL; Gold MA; McMeekin DS; Huh WK; Powell MA; Lewin SN; Mutch DG; Johnson GA; Walker JL; Mannel RS
Gynecol Oncol; 2006 Jan; 100(1):128-32. PubMed ID: 16213011
[TBL] [Abstract][Full Text] [Related]
16. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
Koussounadis A; Langdon SP; Um I; Kay C; Francis KE; Harrison DJ; Smith VA
BMC Cancer; 2016 Mar; 16():205. PubMed ID: 26964739
[TBL] [Abstract][Full Text] [Related]
17. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
[TBL] [Abstract][Full Text] [Related]
18. Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature.
Loizzi V; Cormio G; Camporeale A; Falagario M; De Mitri P; Scardigno D; Putignano G; Selvaggi LE
Oncology; 2011; 80(1-2):102-6. PubMed ID: 21677454
[TBL] [Abstract][Full Text] [Related]
19. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.
Moisan F; Francisco EB; Brozovic A; Duran GE; Wang YC; Chaturvedi S; Seetharam S; Snyder LA; Doshi P; Sikic BI
Mol Oncol; 2014 Oct; 8(7):1231-9. PubMed ID: 24816187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
